文献速递耳科与耳神经

丹参酮ⅡA激活PI3K/AKT信号通路抑制高糖诱导的小鼠耳蜗周细胞凋亡

[Tanshinone ⅡA activates PI3K/AKT signaling pathway to inhibit the apoptosis of mice cochlear pericytes induced by high glucose].
PubMed 文献 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2023-01-01

该研究以C57BL/6J雄性小鼠制备2型糖尿病模型(每组10只)并培养原代耳蜗血管纹周细胞,观察丹参酮ⅡA对高糖诱导周细胞凋亡的保护作用及机制。结果显示丹参酮ⅡA可降低DM组听力阈值、减轻耳蜗氧化应激和血迷路屏障通透性、减少周细胞凋亡,且呈浓度依赖性;LY294002可逆转其保护作用。结论认为丹参酮ⅡA通过降低氧化应激和激活PI3K/AKT通路抑制高糖诱导的周细胞凋亡,从而对糖尿病性听力损失发挥保护作用。

要点

  • 丹参酮ⅡA降低DM组听力阈值(35.0±3.5 vs 55.3±8.1 dB SPL,P<0.01)。
  • 丹参酮ⅡA缓解DM小鼠耳蜗血迷路屏障通透性(Evans blue渗漏6.84±0.27 vs 8.59±0.85 AU,P<0.05)。
  • LY294002可逆转丹参酮ⅡA对周细胞凋亡的保护作用(P值均<0.05)。

核心结论

  • 丹参酮ⅡA可通过降低高糖环境下的氧化应激水平以及激活PI3K/AKT信号通路,抑制高糖诱导的小鼠耳蜗血管纹周细胞凋亡。
  • 丹参酮ⅡA从而发挥对糖尿病性听力损失的保护作用。

研究设计与样本

  • 动物实验:C57BL/6J雄性小鼠40只,分为正常(NG)组、糖尿病(DM)组、糖尿病+丹参酮ⅡA组、丹参酮ⅡA组,每组10只,制备2型糖尿病模型。
  • 细胞实验:原代耳蜗周细胞分为NG组、高糖(HG,35 mmol/L)组、HG+丹参酮ⅡA(1、3、5 μmol/L)组、HG+丹参酮ⅡA+LY294002(PI3K/AKT通路抑制剂)组、LY294002组、丹参酮ⅡA组、二甲基亚砜(DMSO)组。
  • 检测方法包括听性脑干反应(ABR)、Evans blue检测血迷路屏障通透性、硫代巴比妥酸试验(TBA)检测氧化应激、苏木精-伊红染色(HE)、免疫荧光、流式细胞术、DCFH-DA结合流式细胞术检测活性氧(ROS)、免疫蛋白印记(Western blot,WB)。
  • 采用SPSS软件行独立样本t检验,以P<0.05为差异有统计学意义。

主要发现

  • 丹参酮ⅡA降低DM组听力阈值[(35.0±3.5)dB SPL比(55.3±8.1)dB SPL,t=4.899,P<0.01]。
  • 丹参酮ⅡA降低耳蜗内氧化应激水平(t=4.384,P<0.05),改善耳蜗血管纹结构紊乱、萎缩、空泡增多现象。
  • 丹参酮ⅡA缓解DM小鼠耳蜗血管纹血迷路屏障通透性增加[Evans blue渗漏(6.84±0.27)AU比(8.59±0.85)AU,t=2.770,P<0.05]。
  • 丹参酮ⅡA逆转周细胞凋亡蛋白Cleaved-caspase3(t=4.956,P<0.01)和Bax(t=4.388,P<0.05)的表达。
  • 细胞实验中丹参酮ⅡA降低高糖干预下周细胞内ROS含量,且呈浓度依赖性(t=3.569,P<0.05;t=4.772,P<0.01;t=7.494,P<0.01);降低凋亡率和凋亡蛋白、增加抗凋亡蛋白及p-PI3K/PI3K和p-AKT/AKT表达,均呈浓度依赖性(P值均<0.05);LY294002可逆转丹参酮ⅡA对周细胞凋亡的保护作用(P值均<0.05)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate whether tanshinone ⅡA can protect the apoptosis of mice cochlear pericytes induced by high glucose and its specific protective mechanism, so as to provide experimental evidence for the prevention and treatment of diabetic hearing loss. Methods: C57BL/6J male mice were used to prepare type 2 diabetes model, which were divided into normal (NG) group, diabetic (DM) group, diabetic+tanshinone ⅡA (HG+tanshinone ⅡA) group and tanshinone ⅡA group. Each group had 10 animals. Primary cochlear pericytes were divided into NG group, HG group (high glucose 35 mmol/L), HG+tanshinone ⅡA (1, 3, 5 μmol/L) group, HG+Tanshinone ⅡA+LY294002 (PI3K/AKT pathway inhibitor) group, LY294002 group, tanshinone ⅡA group and DMSO group. Auditory brainstem response (ABR) was used to measure hearing threshold. Evans blue was used to detect the permeability of blood labyrinth barrier in each group. TBA methods were used to detect oxidative stress levels in various organs of mice. Morphological changes of stria vascularis were observed by hematoxylin-eosin staining (HE). Evans blue was used to detect the vascular labyrinth barrier permeability in cochlea. The expression of apoptosis protein in stria vascularis pericytes was observed by immunofluorescence. Pericytes apoptosis rate was observed by flow cytometry. DCFH-DA was combined with flow cytometry to detect intracellular ROS content, and Western blot was used to detect the expression of apoptotic proteins (Cleaved-caspase3, Bax), anti-apoptotic proteins (BCL-2) and pathway proteins (PI3K, p-PI3K, AKT, p-AKT). SPSS software was used for statistical analysis. Independent sample t test was performed, and P<0.05 was considered statistically significant. Results: Animal experiments: Tanshinone ⅡA decreased the hearing threshold of DM group [(35.0±3.5) dB SPL vs. (55.3±8.1) dB SPL] (t=4.899, P<0.01), decreased the oxidative stress level in cochlea (t=4.384, P<0.05), improved the structure disorder, atrophy of cochlea vascular lines, vacuole increased phenomenon. Tanshinone ⅡA alleviated the increased permeability of the blood labyrinth barrier [Evans blue leakage (6.84±0.27) AU vs. (8.59±0.85) AU] in the cochlea of DM mice (t=2.770, P<0.05), reversed the apoptotic protein: Caspase3 (t=4.956, P<0.01) and Bax (t=4.388, P<0.05) in cochlear vascularis. Cell experiments: Tanshinone ⅡA decreased intracellular ROS content in a concentration-dependent way (t=3.569, P<0.05; t=4.772, P<0.01; t=7.494, P<0.01); Tanshinone ⅡA decreased apoptosis rate and apoptotic protein, and increased the expression of anti-apoptotic protein, p-PI3K/PI3K and p-AKT/AKT in concentration-dependent manner (all P values<0.05); LY294002 reversed the protective effect of tanshinone ⅡA on pericytes apoptosis (all P values<0.05). Conclusion: Tanshinone ⅡA can inhibit the apoptosis of cochlear pericytes induced by high glucose by reducing oxidative stress level and activating PI3K/AKT signaling pathway under high glucose environment, thus playing a protective role in diabetic hearing loss. 目的: 探讨丹参酮ⅡA是否能抑制高糖诱导的小鼠耳蜗血管纹周细胞的凋亡及可能机制,为治疗糖尿病性听力损失提供参考。 方法: C57BL/6J雄性小鼠40只,分为对照组、糖尿病(DM)组、糖尿病+丹参酮ⅡA组、丹参酮ⅡA组,每组10只。制备2型糖尿病模型。将原代周细胞分为对照组、高糖(HG)组、HG+丹参酮ⅡA(1、3、5 μmol/L)组、HG+丹参酮ⅡA+LY294002(PI3K/AKT通路抑制剂)组、LY294002组、丹参酮ⅡA组、二甲基亚砜(DMSO)组。ABR检测听力阈值;硫代巴比妥酸试验(thiobarbituric acid,TBA)检测耳蜗氧化应激水平;苏木精-伊红染色(HE)观察耳蜗血管纹形态变化;Evans blue检测耳蜗血管纹血迷路屏障通透性;免疫荧光观察耳蜗血管纹周细胞凋亡蛋白的表达;流式细胞术检测周细胞凋亡率;DCFH-DA结合流式细胞术检测周细胞内活性氧(reactive oxygen species,ROS)含量,免疫蛋白印记(Western Blot,WB)法检测周细胞凋亡蛋白(Cleaved-caspase3、Bax)、抗凋亡蛋白(BCL-2)以及通路蛋白(PI3K、p-PI3K、AKT、p-AKT)的表达。采用 SPSS软件进行统计分析,行独立样本t检验,以P<0.05为差异有统计学意义。 结果: 动物实验:丹参酮ⅡA可降低DM组[(35.0±3.5)dB SPL比(55.3±8.1)dB SPL]听力阈值(t=4.899,P<0.01),降低耳蜗内氧化应激水平(t=4.384,P<0.05),改善耳蜗血管纹结构紊乱、萎缩,空泡增多的现象。丹参酮ⅡA可缓解DM小鼠耳蜗血管纹血迷路屏障通透性[Evans blue渗漏(6.84±0.27)AU比(8.59±0.85)AU]增加的现象(t=2.770,P<0.05),可逆转周细胞凋亡蛋白Cleaved-caspase3(t=4.956,P<0.01)和 Bax(t=4.388,P<0.05)的表达。细胞实验:丹参酮ⅡA可降低高糖干预下的周细胞内ROS含量,且呈浓度依赖性(t=3.569,P<0.05;t=4.772,P<0.01;t=7.494,P<0.01);丹参酮ⅡA可降低高糖干预下的周细胞凋亡率和凋亡蛋白,增加抗凋亡蛋白、p-PI3K/PI3K和p-AKT/AKT的表达,且均呈浓度依赖性(P值均<0.05);LY294002可逆转丹参酮ⅡA对周细胞凋亡的保护作用(P值均<0.05)。 结论: 丹参酮ⅡA可通过降低高糖环境下的氧化应激水平以及激活PI3K/AKT信号通路,抑制高糖诱导的小鼠耳蜗血管纹周细胞凋亡,从而发挥对糖尿病性听力损失的保护作用。.

来源:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shi TF, Jia JJ, Huang TL, et al. [Tanshinone ⅡA activates PI3K/AKT signaling pathway to inhibit the apoptosis of mice cochlear pericytes induced by high glucose]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023. PMID: 37455113. doi:10.3760/cma.j.cn115330-20230115-00022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。